INGAVIRIN CAPSULES 60MG
INGAVIRIN CAPSULES 60MG - 10 pcs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Trade name of the drug: Ingavirin
International non-proprietary or grouping name:
Imidazolyl ethanamide pentanedioic acid
Dosage Form: capsules
The composition of one capsule
One capsule contains:
Active ingredient: Imidazolyl ethanamide pentanedioic acid (vitaglutam) in terms of 100% substance - 60.00 mg;
Excipients: lactose monohydrate - 60.00 mg, potato starch - 23.72 mg, colloidal silicon dioxide (aerosil) -1.47 mg, Magnesium stearate - 1.47;
Hard gelatin capsules:
Titanium dioxide E 171-1,0000%, iron dye yellow oxide E 172-1,0000%, gelatin-up to 100%
The composition of the ink for the logo: shellac, propylene glycol E 1520, titanium dioxide E 171.
Pharmacological properties Pharmacodynamics
In preclinical and clinical studies, the effectiveness of the drug Ingavirin in the treatment of influenza A viruses (A (H1N1), including "Pork" A (H1N1)pdm09, A (H3N2), A (H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enterovirus, including Coxsackie virus and rhinovirus.
The drug Ingavirin contributes to the accelerated elimination of viruses, reducing the duration of the disease, reducing the risk of complications.
The mechanism of action at the level of infected cells due to the stimulation of innate immunity factors suppressed by viral proteins.
The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a local irritating effect. The drug Ingavirin does not affect the reproductive function, does not have embryotoxic and teratogenic effects.
Efficacy in children
In a double-blind, randomized, placebo-controlled, multicenter study evaluating the clinical efficacy and safety of Ingavirin at a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections in 180 children aged 7-17 years, it was shown that Ingavirin was significantly superior to placebo, faster normalizing body temperature, arresting intoxication, fever, catarrhal phenomena.A double-blind, randomized, placebo-controlled, multicenter study evaluating the clinical efficacy and safety of the drug Ingavirin at a daily dose of 60 mg for the treatment of influenza other acute respiratory viral infections in 310 children aged 7-12 years has shown that Ingavirin has a significantly greater efficacy compared with placebo and provides a faster (on average 18 hours) decrease in body temperature and the disappearance of symptoms of intoxication (sore throat, sore throat, pain when swallowing, nasal congestion, runny nose).
Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection) in children from 7 to 17 years old.
Hypersensitivity to the active substance or any other component of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Children's age up to 7 years.
This dosage form is not intended for use in persons 18 years and older (it is necessary to use dosage forms that provide the possibility of taking the drug Ingavirin 90 mg.).
Pregnancy and breastfeeding
The use of the drug during pregnancy has not been studied. The use of the drug during lactation has not been studied, so if necessary, use of the drug during lactation should stop breastfeeding.
Dosage and administration
Inside Regardless of the meal.
For the treatment of influenza and acute respiratory viral infections, children from 7 to 17 years old are prescribed 1 capsule (60 mg) 1 time per day. The duration of treatment is 5-7 days (depending on the severity of the condition). The drug intake is started from the moment the first symptoms of the disease appear, preferably not later than 2 days from the onset of the disease.
Allergic reactions (rare)
Cases of drug overdose Ingavirin so far not reported.
Interaction with other drugs
Drug interactions drug Ingavirin is not described.
It is not recommended to take other antiviral drugs at the same time.
Influence on ability to use vehicles, mechanisms
Not studied, however, given the mechanism of action and the profile of adverse reactions, it can be suggested that the drug does not affect the ability to drive vehicles, mechanisms.
In the dark place at a temperature of no higher than 250C. Keep out of the reach of children.